Advanced search

Online first
Invited Review Article
Published online: 2025-01-09

open access

View PDF Download PDF file
Supp./Additional Files
Page views 494
Article views/downloads 372
Get Citation

Connect on Social Media

Connect on Social Media

Long-term effect and reasons for switching and combining device-aided therapies in Parkinson’s Disease

Dejan Georgiev123, Maja Trost13
DOI: 10.5603/pjnns.102858
Pubmed: 39782889

Abstract

Introduction. In the advanced stages of Parkinson’s disease (PD), when standard drug adjustments fail to sufficiently improve patients’ quality of life, device-aided therapies (DATs) such as deep brain stimulation (DBS), continuous subcutaneous apomorphine infusion (CSAI), levodopa-carbidopa intestinal gel infusion (LCIG), levodopa-carbidopa-entacapone intestinal gel infusion, or continuous subcutaneous foslevodoa-foscarbidopa infusion are beneficial in the long run. However, sometimes patients need to switch or combine DATs due to either adverse events or loss of efficacy.

Aim of study. The aim of this article was to summarise the existing data on the long-term efficacy and adverse events of DATs, and to review the data on the rationale and efficacy for switching or combining DATs in advanced PD.

State of the art. A total of 50 studies on the long-term efficacy of DBS (N = 28), LCIG (N = 12), CSAI (N = 10) and 13 studies on switching and combining DATs were included in this review. Although the DATs show a favourable long-term effect on the main motor and non-motor symptoms of PD they all feature specific adverse events that need to be considered when deciding which DAT to offer to a particular patient. Occasionally, switching or combining DATs is recommended, e.g. if the first DAT shows inadequate symptom control, or due to adverse events. The choice of the second DAT depends above all on the main problems of the first DAT being correctly recognised.

Clinical implications. DATs are a safe and long-term effective option for the treatment of advanced PD. Switching and/or combining DATs is recommended for patients in whom the first treatment option is not optimal.

Future directions. Future studies are warranted to address the unresolved issues related to long-term efficacy, side effect profile and switching and combination of DATs in multicentric studies and using advanced analytical approaches such as machine learning.

Keywords: advanced Parkinson’s Diseasedevice-aided therapieslong-term effect of device-aided therapiesswitches and combinations of device-aided therapies

Article available in PDF format

View PDF Download PDF file

References

  1. Kalia LV, Lang AE. Lang AE. Parkinson's disease Lancet 2015;386. ; 9996: 896–912.
  2. Malaty IA, Martinez-Martin P, Chaudhuri KR, et al. Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries. BMC Neurol. 2022; 22(1): 35.
    CrossRefPubMed
  3. Antonini A, Stoessl AJ, Kleinman LS, et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach. Curr Med Res Opin. 2018; 34(12): 2063–2073.
    CrossRefPubMed
  4. Limousin P, Foltynie T. Long-term outcomes of deep brain stimulation in Parkinson disease. Nature Reviews Neurology. 2019; 15(4): 234–242.
    CrossRef
  5. Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord. 1993; 8(2): 165–170.
    CrossRefPubMed
  6. Antonini A, Odin P, Pahwa R, et al. The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review. Adv Ther. 2021; 38(6): 2854–2890.
    CrossRefPubMed
  7. Szász JA, Dulamea AO, Constantin VA, et al. Levodopa-Carbidopa-Entacapone Intestinal Gel in Advanced Parkinson Disease: A Multicenter Real-Life Experience. Am J Ther. 2024; 31(3): e209–e218.
    CrossRefPubMed
  8. Soileau MJ, Aldred J, Budur K, et al. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol. 2022; 21(12): 1099–1109.
    CrossRefPubMed
  9. Moro E, Lozano AM, Pollak P, et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord. 2010; 25(5): 578–586.
    CrossRefPubMed
  10. Laar Tv, Chaudhuri K, Antonini A, et al. Infusion Therapies in the Treatment of Parkinson’s Disease. Journal of Parkinson's Disease. 2023; 13(5): 641–657.
    CrossRef
  11. Kukkle PL, Garg D, Merello M. Continuous Subcutaneous Infusion Delivery of Apomorphine in Parkinson's Disease: A Systematic Review. Mov Disord Clin Pract. 2023; 10(9): 1253–1267.
    CrossRefPubMed
  12. Antonini A, Pahwa R, Odin P, et al. Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson's Disease: A Systematic Review and Bayesian Network Meta-analysis. CNS Drugs. 2022; 36(12): 1269–1283.
    CrossRefPubMed
  13. Nijhuis FAP, Esselink R, de Bie RMA, et al. Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta-Analysis. Mov Disord. 2021; 36(6): 1293–1307.
    CrossRefPubMed
  14. Aviles-Olmos I, Kefalopoulou Z, Tripoliti E, et al. Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson's disease using an MRI-guided and MRI-verified approach. J Neurol Neurosurg Psychiatry. 2014; 85(12): 1419–1425.
    CrossRefPubMed
  15. Castrioto A, Lozano AM, Poon YY, et al. Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol. 2011; 68(12): 1550–1556.
    CrossRefPubMed
  16. de Noordhout AM, Mouchamps M, Remacle JM, et al. Subthalamic deep brain stimulation versus best medical treatment: a 12-year follow-up. Acta Neurol Belg. 2022; 122(1): 197–202.
    CrossRefPubMed
  17. Fasano A, Romito LM, Daniele A, et al. Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. Brain. 2010; 133(9): 2664–2676.
    CrossRefPubMed
  18. Georgiev D, Mencinger M, Rajnar R, et al. Long-term effect of bilateral STN-DBS on non-motor symptoms in Parkinson's disease: A four-year observational, prospective study. Parkinsonism Relat Disord. 2021; 89: 13–16.
    CrossRefPubMed
  19. Gervais-Bernard H, Xie-Brustolin J, Mertens P, et al. Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: five year follow-up. J Neurol. 2009; 256(2): 225–233.
    CrossRefPubMed
  20. Hacker ML, Tramontana MG, Pazira K, et al. Long-term neuropsychological outcomes of deep brain stimulation in early-stage Parkinson's disease. Parkinsonism Relat Disord. 2023; 113: 105479.
    CrossRefPubMed
  21. Jost S, Chaudhuri KR, Ashkan K, et al. Subthalamic Stimulation Improves Quality of Sleep in Parkinson Disease: A 36-Month Controlled Study. Journal of Parkinson's Disease. 2021; 11(1): 323–335.
    CrossRef
  22. Jost ST, Sauerbier A, Visser-Vandewalle V, et al. EUROPAR and the International Parkinson and Movement Disorders Society Non-Motor Parkinson's Disease Study Group. A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease: results at the 36-month follow-up. J Neurol Neurosurg Psychiatry. 2020; 91(7): 687–694.
    CrossRefPubMed
  23. Kishore A, Rao R, Krishnan S, et al. Long-term stability of effects of subthalamic stimulation in Parkinson's disease: Indian Experience. Mov Disord. 2010; 25(14): 2438–2444.
    CrossRefPubMed
  24. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 2003; 349(20): 1925–1934.
    CrossRefPubMed
  25. Lezcano E, Gómez-Esteban JC, Tijero B, et al. Long-term impact on quality of life of subthalamic nucleus stimulation in Parkinson's disease. J Neurol. 2016; 263(5): 895–905.
    CrossRefPubMed
  26. Rizzone MG, Fasano A, Daniele A, et al. Long-term outcome of subthalamic nucleus DBS in Parkinson's disease: from the advanced phase towards the late stage of the disease? Parkinsonism Relat Disord. 2014; 20(4): 376–381.
    CrossRefPubMed
  27. Romito LM, Contarino MF, Vanacore N, et al. Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: long-term observation. Mov Disord. 2009; 24(4): 557–563.
    CrossRefPubMed
  28. Schüpbach WMM, Chastan N, Welter ML, et al. Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry. 2005; 76(12): 1640–1644.
    CrossRefPubMed
  29. Volkmann J, Allert N, Voges J, et al. Long-term results of bilateral pallidal stimulation in Parkinson's disease. Ann Neurol. 2004; 55(6): 871–875.
    CrossRefPubMed
  30. Wider C, Pollo C, Bloch J, et al. Long-term outcome of 50 consecutive Parkinson's disease patients treated with subthalamic deep brain stimulation. Parkinsonism Relat Disord. 2008; 14(2): 114–119.
    CrossRefPubMed
  31. Yamamoto T, Uchiyama T, Higuchi Y, et al. Long term follow-up on quality of life and its relationship to motor and cognitive functions in Parkinson's disease after deep brain stimulation. J Neurol Sci. 2017; 379: 18–21.
    CrossRefPubMed
  32. Zibetti M, Merola A, Rizzi L, et al. Beyond nine years of continuous subthalamic nucleus deep brain stimulation in Parkinson's disease. Mov Disord. 2011; 26(13): 2327–2334.
    CrossRefPubMed
  33. Stern MB, Follett KA, Weaver FM, et al. CSP 468 Study Group. Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology. 2012; 79(1): 55–65.
    CrossRefPubMed
  34. Bang Henriksen M, Johnsen EL, Sunde N, et al. Surviving 10 years with deep brain stimulation for Parkinson's disease--a follow-up of 79 patients. Eur J Neurol. 2016; 23(1): 53–61.
    CrossRefPubMed
  35. Barbosa R, Guedes LC, Cattoni MB, et al. Long-term follow-up of subthalamic nucleus deep brain stimulation in patients with Parkinson's disease: An analysis of survival and disability milestones. Parkinsonism Relat Disord. 2024; 118: 105921.
    CrossRefPubMed
  36. Bonenfant J, Drapier S, Houvenaghel JF, et al. Pallidal stimulation in Parkinson's patients with contraindications to subthalamic target: A 3 years follow-up. Parkinsonism Relat Disord. 2017; 34: 20–25.
    CrossRefPubMed
  37. Bove F, Fraix V, Cavallieri F, et al. Dementia and subthalamic deep brain stimulation in Parkinson disease: A long-term overview. Neurology. 2020; 95(4): e384–e392.
    CrossRefPubMed
  38. Bove F, Mulas D, Cavallieri F, et al. Long-term Outcomes (15 Years) After Subthalamic Nucleus Deep Brain Stimulation in Patients With Parkinson Disease. Neurology. 2021; 97(3): e254–e262.
    CrossRefPubMed
  39. Cavallieri F, Fraix V, Bove F, et al. Predictors of Long‐Term Outcome of Subthalamic Stimulation in Parkinson Disease. Annals of Neurology. 2021; 89(3): 587–597.
    CrossRef
  40. Zampogna A, Suppa A, Bove F, et al. Disentangling Bradykinesia and Rigidity in Parkinson's Disease: Evidence from Short- and Long-Term Subthalamic Nucleus Deep Brain Stimulation. Ann Neurol. 2024; 2024(2): 234–246.
  41. Chen Y, Gong C, Tian Ye, et al. Neuromodulation effects of deep brain stimulation on beta rhythm: A longitudinal local field potential study. Brain Stimul. 2020; 13(6): 1784–1792.
    CrossRefPubMed
  42. Kolmančič K, Zupančič NK, Trošt M, et al. Continuous Dopaminergic Stimulation Improves Cortical Maladaptive Changes in Advanced Parkinson's Disease. Mov Disord. 2022; 37(7): 1465–1473.
    CrossRefPubMed
  43. Buongiorno M, Antonelli F, Cámara A, et al. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry. Parkinsonism Relat Disord. 2015; 21(8): 871–876.
    CrossRefPubMed
  44. Chaudhuri KR, Kovács N, Pontieri FE, et al. Levodopa Carbidopa Intestinal Gel in Advanced Parkinson's Disease: DUOGLOBE Final 3-Year Results. J Parkinsons Dis. 2023; 13(5): 769–783.
    CrossRefPubMed
  45. De Fabregues O, Dot J, Abu-Suboh M, et al. Long-term safety and effectiveness of levodopa-carbidopa intestinal gel infusion. Brain Behav. 2017; 7(8): e00758.
    CrossRefPubMed
  46. Fernandez HH, Boyd JT, Fung VSC, et al. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease. Mov Disord. 2018; 33(6): 928–936.
    CrossRefPubMed
  47. Lopiano L, Modugno N, Marano P, et al. Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study. J Neurol. 2019; 266(9): 2164–2176.
    CrossRefPubMed
  48. Slevin JT, Fernandez HH, Zadikoff C, et al. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients. J Parkinsons Dis. 2015; 5(1): 165–174.
    CrossRefPubMed
  49. Standaert DG, Rodriguez RL, Slevin JT, et al. Effect of Levodopa-carbidopa Intestinal Gel on Non-motor Symptoms in Patients with Advanced Parkinson's Disease. Mov Disord Clin Pract. 2017; 4(6): 829–837.
    CrossRefPubMed
  50. Zibetti M, Merola A, Artusi CA, et al. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience. Eur J Neurol. 2014; 21(2): 312–318.
    CrossRefPubMed
  51. Fasano A, García-Ramos R, Gurevich T, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: long-term results from COSMOS. J Neurol. 2023; 270(5): 2765–2775.
    CrossRefPubMed
  52. Garrì F, Russo FP, Carrer T, et al. Long-term safety, discontinuation and mortality in an Italian cohort with advanced Parkinson's disease on levodopa/carbidopa intestinal gel infusion. J Neurol. 2022; 269(10): 5606–5614.
    CrossRefPubMed
  53. Rus T, Premzl M, Križnar NZ, et al. Adverse effects of levodopa/carbidopa intrajejunal gel treatment: A single-center long-term follow-up study. Acta Neurol Scand. 2022; 146(5): 537–544.
    CrossRefPubMed
  54. Antonini A, Marano P, Gusmaroli G, et al. Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson's disease: results of the Italian GLORIA patient population. Neurol Sci. 2020; 41(10): 2929–2937.
    CrossRefPubMed
  55. Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J Neurol Neurosurg Psychiatry. 1998; 65(5): 709–716.
    CrossRefPubMed
  56. Sesar Á, Fernández-Pajarín G, Ares B, et al. Continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: 10-year experience with 230 patients. J Neurol. 2017; 264(5): 946–954.
    CrossRefPubMed
  57. Bhidayasiri R, Phokaewvarangkul O, Boonpang K, et al. Long-term Apomorphine Infusion Users Versus Short-term Users: An International Dual-center Analysis of the Reasons for Discontinuing Therapy. Clin Neuropharmacol. 2019; 42(5): 172–178.
    CrossRefPubMed
  58. Borgemeester RWK, van Laar T. Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study. Parkinsonism Relat Disord. 2017; 45: 33–38.
    CrossRefPubMed
  59. Camgrand E, Christine BC, Harroch E, et al. Discontinuation rate and long-term adverse events path of apomorphine infusion in advanced Parkinson's disease patients. Parkinsonism Relat Disord. 2023; 116: 105859.
    CrossRefPubMed
  60. García Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord. 2008; 23(8): 1130–1136.
    CrossRefPubMed
  61. Henriksen T, Staines H. Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease: A Single-Center, Long-Term Follow-Up Study of the Causes for Discontinuation. J Pers Med. 2021; 11(6).
    CrossRefPubMed
  62. Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord. 2002; 17(6): 1235–1241.
    CrossRefPubMed
  63. Meira B, Degos B, Corsetti E, et al. Long-term effect of apomorphine infusion in advanced Parkinson's disease: a real-life study. NPJ Parkinsons Dis. 2021; 7(1): 50.
    CrossRefPubMed
  64. Bautista JM, Oyama G, Nuermaimaiti M, et al. Rescue Levodopa/Carbidopa Intestinal Gel for Secondary Deep Brain Stimulation Failure. J Mov Disord. 2020; 13(1): 57–61.
    CrossRefPubMed
  65. Boura I, Haliasos N, Giannopoulou Io, et al. Combining Device-Aided Therapies in Parkinson's Disease: A Case Series and a Literature Review. Mov Disord Clin Pract. 2021; 8(5): 750–757.
  66. Elkouzi A, Ramirez-Zamora A, Zeilman P, et al. Rescue levodopa-carbidopa intestinal gel (LCIG) therapy in Parkinson's disease patients with suboptimal response to deep brain stimulation. Ann Clin Transl Neurol. 2019; 6(10): 1989–1995.
    CrossRefPubMed
  67. Klostermann F, Jugel C, Marzinzik F. Jejunal levodopa infusion in long-term DBS patients with Parkinson's disease. Mov Disord. 2011; 26(12): 2298–2299.
    CrossRefPubMed
  68. Kumar N, Murgai A, Naranian T, et al. Levodopa-carbidopa intestinal gel therapy after deep brain stimulation. Mov Disord. 2018; 33(2): 334–335.
    CrossRefPubMed
  69. Varma TRK, Fox SH, Eldridge PR, et al. Deep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson's disease patients previously reliant on apomorphine. J Neurol Neurosurg Psychiatry. 2003; 74(2): 170–174.
    CrossRefPubMed
  70. van Poppelen D, Tromp ANM, de Bie RMA, et al. Combined and Sequential Treatment with Deep Brain Stimulation and Continuous Intrajejunal Levodopa Infusion for Parkinson's Disease. J Pers Med. 2021; 11(6).
    CrossRefPubMed
  71. Mulroy E, Leta V, Zrinzo L, et al. Successful Treatment of Levodopa/Carbidopa Intestinal Gel Associated "Biphasic-like" Dyskinesia with Pallidal Deep Brain Stimulation. Mov Disord Clin Pract. 2021; 8(2): 273–274.
    CrossRefPubMed
  72. Georgiev D, Delalić S, Zupančič Križnar N, et al. Switching and Combining Device-Aided Therapies in Advanced Parkinson's Disease: A Double Centre Retrospective Study. Brain Sci. 2022; 12(3).
    CrossRefPubMed
  73. Sesar Á, Fernández-Pajarín G, Ares B, et al. Continuous subcutaneous apomorphine in advanced Parkinson's disease patients treated with deep brain stimulation. J Neurol. 2019; 266(3): 659–666.
    CrossRefPubMed
  74. Pürner D, Hormozi M, Weiß D, et al. Nationwide Retrospective Analysis of Combinations of Advanced Therapies in Patients With Parkinson Disease. Neurology. 2023; 101(21): e2078–e2093.
    CrossRefPubMed
  75. Regidor I, Benita V, Del Álamo de Pedro M, et al. Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation-Refractory Symptoms in Advanced Parkinson Disease. Clin Neuropharmacol. 2017; 40(3): 103–107.
    CrossRefPubMed
  76. Fernández-Pajarín G, Sesar Á, Jiménez Martín I, et al. Continuous subcutaneous apomorphine infusion in the early phase of advanced Parkinson's disease: A prospective study of 22 patients. Clin Park Relat Disord. 2022; 6: 100129.
    CrossRefPubMed
  77. Deuschl G, Antonini A, Costa J, et al. European Academy of Neurology/Movement Disorder Society - European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies. Eur J Neurol. 2022; 29(9): 2580–2595.
    CrossRefPubMed
  78. Moosa S, Martínez-Fernández R, Elias WJ, et al. The role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson's disease. Mov Disord. 2019; 34(9): 1243–1251.
    CrossRefPubMed
  79. Hariz M, Cif L, Blomstedt P. Thirty Years of Global Deep Brain Stimulation: "Plus ça change, plus c'est la même chose"? Stereotact Funct Neurosurg. 2023; 101(6): 395–406.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2025 Via Medica Regulations Cookie policy Privacy Statement Legal Note